GSK has been the topic of several other research reports. Barclays set a GBX 1,750 ($22.87) price objective on shares of GlaxoSmithKline and gave the company a buy rating in a research report on Monday, July 23rd. Societe Generale set a GBX 1,000 ($13.07) price objective on shares of GlaxoSmithKline and gave the company a sell rating in a research report on Monday, September 10th. UBS Group restated a buy rating and set a GBX 1,700 ($22.21) price objective on shares of GlaxoSmithKline in a research report on Thursday, September 27th. Shore Capital upgraded shares of GlaxoSmithKline from an average rating to a buy rating and set a GBX 41.74 ($0.55) price objective on the stock in a research report on Thursday, July 26th. Finally, Cfra set a GBX 1,550 ($20.25) price objective on shares of GlaxoSmithKline and gave the company a neutral rating in a research report on Thursday, July 26th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. GlaxoSmithKline has an average rating of Hold and an average target price of GBX 1,527.84 ($19.96).
GlaxoSmithKline stock opened at GBX 1,554.80 ($20.32) on Monday. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($16.14) and a fifty-two week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.